A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty.
about
Insights from molecular dynamics simulations to exploit new trends for the development of improved opioid drugs.Efficacy and Safety of Intravenous Meloxicam in Subjects with Moderate-to-severe Pain Following AbdominoplastyNociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesicInner Workings: Safer opioids may be on the horizon, but mitigating addiction is a long shot
P2860
A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
A randomized, Phase IIb study ...... pain following abdominoplasty.
@en
A randomized, Phase IIb study ...... pain following abdominoplasty.
@nl
type
label
A randomized, Phase IIb study ...... pain following abdominoplasty.
@en
A randomized, Phase IIb study ...... pain following abdominoplasty.
@nl
prefLabel
A randomized, Phase IIb study ...... pain following abdominoplasty.
@en
A randomized, Phase IIb study ...... pain following abdominoplasty.
@nl
P2093
P2860
P356
P1476
A randomized, Phase IIb study ...... pain following abdominoplasty.
@en
P2093
David A Burt
David G Soergel
Franck Skobieranda
Harold S Minkowitz
Michael J Fossler
Monica Y Salamea
Neil Singla
Ruth Ann Subach
P2860
P304
P356
10.2147/JPR.S137952
P577
2017-10-06T00:00:00Z